Comment: What a change a few weeks can bring
Jonathan Kell
pp 23-23
What a change a few weeks can bring – since writing my first editorial for this journal, the UK has voted to leave the EU, plunging healthcare funding and investment research into something of a dark age with great uncertainty for the future.
|
NICE guideline on non-Hodgkin’s lymphoma
Jackie Green
pp 24-25
Non-Hodgkin’s lymphoma is the sixth most common cancer in the UK. The disease has many subtypes, which have very different clinical outcomes and requirements for treatment. This makes diagnosing the exact subtype essential for improving and optimising management and outcomes.
|
MDS UK
Kes Grant
pp 26-26
As haematologists, how do you work with feisty patients who have a mind of their own? It can be challenging, but if the haematologist and patient meet halfway, it can end up being a very productive working relationship that benefits both parties and from which both can learn so much.
|
What I tell my patients about nutrition in haematological cancers
Laura Coster
pp 27-29
Nutrition is an important, but often overlooked, area of health that focuses on providing the body with the nutrients it requires to maintain its basic functions, and help it cope with states of disease. This article focuses on nutrition for patients with cancer, with particular attention to those with haematological cancers. Cancer-related nutrition management can be divided into two main categories: optimising diet for the prevention of disease and managing signs and symptoms. The role of the oncology specialist dietitian focuses on treating malnutrition in patients with cancer to help support their recovery or palliative care.
|
Life as a clinical trials fellow
Dr Ali Mahdi
pp 30-30
I have now been working at the Clinical Research Facility in Cardiff for almost 12 months. The role involves supporting the trial activity for patients with haematological malignancies, working at various stages of development. This ranges from complex ‘first in man’ to larger and more established Phase III studies.
|
Therapeutic developments for Hodgkin’s lymphoma
Graham P Collins
pp 31-34
Classical Hodgkin’s lymphoma is an uncommon malignancy, with an age-adjusted incidence in the USA and Europe of 0.7 per 100,000 population in females and 1.1 per 100,000 in males. It has, however, attracted considerable interest, partly because it is one of the commonest cancers in the teenage and young adult population and partly due to its intriguing biology.
|
Leukaemia CARE – the Cancer Lottery campaign
Zack Pemberton-Whiteley
pp 35-35
Through its Cancer Lottery campaign, Leukaemia CARE has been raising the profile of blood cancer patients’ issues with access to treatment.
|